Ironwood Pharmaceuticals is trading at $3.50 (-6.67%) in after-hours trading, with the cause of the decline unclear. - Its investor-relations page lists no October 7 announcement; its latest listed release is dated September 3. - Earlier coverage discussed Linzess demand and raised 2026 guidance, but did not identify a new catalyst for the decline. - Broader markets were weaker, but supplied index data do not establish a cause; no after-hours volume or activity data was provided.